Abstract
Although clinical response to primary chemotherapy in stage II and III breast cancer is associated with a survival advantage, it is the degree of pathological response in the breast and ipsilateral axilla that best identifies patients with a good long-term outcome. A mathematical model of the initial response of 39 locally advanced tumours to anthracycline-based primary chemotherapy has been previously shown to predict subsequent clinical tumour size. This model allows for the possibility of primary resistant disease, the presence of which should therefore be associated with a worse outcome. This study reports the application of this model to an additional five patients with locally advanced breast cancer, as well as to 63 patients with operable breast cancer, and confirms the biological reality of the model parameters for these 100 breast cancers treated with primary anthracycline-based chemotherapy. The tumours that responded to chemotherapy had higher cell-kill (P < 0.0005), lower resistance (P < 0.0001) and slower tumour regrowth (P < 0.002). Furthermore, ER-negative tumours had higher cell-kill (P < 0.05), as compared with ER-positive tumours. All patients with a pathological complete response had zero resistance according to the model. Furthermore, the long-term implication of chemo-resistant disease was demonstrated by survival analysis of these two groups of patients. At a median follow-up of 3.7 years, there was a statistically significantly worse survival for the 37 patients with locally advanced breast cancer identified by the model to have more than 8% primary resistant tumour (P < 0.003). The specificity of this putative prognostic indicator was confirmed in the 63 patients presenting with operable disease where, at a median follow-up of 7.7 years, those women with a resistant fraction of greater than 8% had a significantly worse survival (P < 0.05). Application of this model to patients treated with neoadjuvant chemotherapy may allow earlier identification of clinically significant resistance and permit intervention with alternative non-cross-resistant therapies such as taxoids. © 2000 Cancer Research Campaign
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Aas, Børresen, Geisler, Smith-Sørensen, Johnsen, Varhaug, Akslen, and Lønning, (1996) Specific p53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nature Medicine 2: 811–814
Anderson, Forrest, Hawkins, Anderson, Leonard, and Chetty, (1991) Primary systemic therapy for operable breast cancer. British Journal of Cancer 63: 561–566
Bélembaogo, Feillel, Chollet, Curé, Verrelle, Kwiatkowski, Achard, Le Bouëdec, Chassagne, Bignon, De Latour, Lafaye, and Dauplat, (1992) Neoadjuvant chemotherapy in 126 operable breast cancers. Eur J Cancer 28A: 896–900
Bonadonna, Valagussa, Brambilla, and Ferrari, (1993) Preoperative chemotherapy in operable breast cancer. Lancet 341: 1485–1485
Bonadonna, Veronesi, Brambilla, Ferrari, Luini, Greco, Bartoli, Coopmans De Yoldi, Zucali, Rilke, Andreola, Silvestrini, Di Fronzo, and Valagussa, (1990) Primary chemotherapy to avoid mastectomy in tumours with diameters of three centimetres or more. Journal of the National Cancer Institute 82: 1539–1545
Cameron, Anderson, Levack, Hawkins, Anderson, Leonard, Forrest, and Chetty, (1997) Primary systemic therapy for operable breast cancer – 10-year survival data following chemotherapy and hormone therapy. Br J Cancer 76: 1099–1105
Cameron, Gregory, Bowman, and Leonard, (1996) Mathematical modelling of tumour response in primary breast cancer. Br J Cancer 73: 1409–1416
Fisher, Brown, Mamounas, Wieand, Robidoux, Margolese, Cruz, Fisher, Wickerham, Wolmark, Decillis, Hoehn, Lees, and Dimitrov, (1997) Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18 [see comments]. Journal of Clinical Oncology 15: 2483–2493
Fisher, Bryant, Wolmark, Mamounas, Brown, Fisher, Wickerham, Begovic, Decillis, Robidoux, Margolese, Cruz, Jr, Hoehn, Lees, Dimitrov, and Bear, (1998) Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. Journal of Clinical Oncology 16: 2672–2685
Forouhi, Dixon, Leonard, and Chetty, (1995) Prospective randomized study of surgical morbidity following primary systemic therapy for breast-cancer. Br J Surgery 82: 79–82
Gabra, Cameron, Lee, Mackay, and Leonard, (1996) Weekly doxorubicin and continuous infusional 5-FU for advanced breast cancer. Br J Cancer 74: 2008–2012
Gregory, Reznek, Hallet, and Slevin, (1990) Using mathematical models to estimate drug resistance and treatment efficacy via CT scan measurements of tumour volume. Br J Cancer 62: 671–675
Makris, Powles, Dowsett, Osborne, Trott, Fernando, Ashley, Ormerod, Titley, Gregory, and Allred, (1997) Prediction of response to neoadjuvant chemoendocrine therapy in primary breast carcinomas. Clinical Cancer Research 3: 593–600
Mauriac, Durand, Avril, and Dilhuydy, (1991) Effects of primary chemotherapy in conservative treatment of breast cancer patients with operable tumours larger than 3 cm. Annals of Oncology 2: 347–354
McGuire, (1991) Breast cancer prognostic factors: evaluation guidelines. J Natl Cancer Inst 83: 154–155
Powles, Hickish, Makris, Ashley, O’Brien, Tidy, Casey, Nash, Sacks, Cosgrove, Macvicar, Fernando, and Ford, (1995) Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer. Journal of Clinical Oncology 13: 547–552
Scholl, Asselain, Beuzeboc, Pierga, Dorval, Garcia-Giralt, Jouve, Palangié, Fourquet, Durand, and Pouillart, (1995) Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for conserving surgery: an update. Anti-Cancer Drugs 6 (Suppl 2): 69
Scholl, Pierga, Asselain, Buezeboc, Dorval, Garcia-Giralt, Jouve, Palangié, Remvikos, Durand, Fourquet, and Pouillart, (1996) Breast tumour response to primary chemotherapy predicts local and distant control as well as survival. Eur J Cancer 31A: 1969–1975
Skipper, (1978). Reasons for Success and Failure in the Treatment of Murine Leukemias with the Drugs Now Employed in Treating Human Leukemias, Vol 1, University Microfilms International: Ann Arbor
Smith, Walsh, Jones, Prendiville, Johnston, Gusterton, Ramage, Robertshaw, Sacks, Ebbs, Mckinna, and Baum, (1995) High complete remission rates with primary neoadjuvant infusional chemotherapy for large early breast cancer. Journal of Clinical Oncology 13: 424–429
Thomlinson, (1982) Measurement and management of carcinoma of the breast. Clinical Radiology 33: 481–493
Thomlinson, (1987) Cancer: the failure of treatment. British Journal of Radiology 60: 735–751
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Cameron, D., Gregory, W., Bowman, A. et al. Identification of long-term survivors in primary breast cancer by dynamic modelling of tumour response. Br J Cancer 83, 98–103 (2000). https://doi.org/10.1054/bjoc.2000.1216
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2000.1216
Keywords
This article is cited by
-
Cell killing and resistance in pre-operative breast cancer chemotherapy
BMC Cancer (2008)
-
From genetic abnormality to metastases: murine models of breast cancer and their use in the development of anticancer therapies
Breast Cancer Research and Treatment (2006)